Cyclooxygenase‐2 selectivity of non‐steroidal anti‐inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident

Aim To assess degree of cyclooxygenase‐2 (COX‐2) selectivity of a non‐steroidal anti‐inflammatory drug (NSAID) and risk of myocardial infarction (MI) or cerebrovascular accident (CVA).

[1]  J. Vane,et al.  Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  D. Rader,et al.  COX-2-Derived Prostacyclin Confers Atheroprotection on Female Mice , 2004, Science.

[3]  Peter J. Richardson,et al.  National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. , 2005, Gastroenterology.

[4]  M. Farkouh,et al.  Cardiovascular effects of selective COX-2 inhibition: is there a class effect? The International COX-2 Study Group. , 2006, The Journal of rheumatology.

[5]  A. Laupacis,et al.  Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study , 2004, The Lancet.

[6]  Sonia Hernández-Díaz,et al.  Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. , 2006, Basic & clinical pharmacology & toxicology.

[7]  P. Allison.  Survival analysis using the SAS system : a practical guide , 1995 .

[8]  J. Fries,et al.  The relative toxicity of nonsteroidal antiinflammatory drugs. , 2010, Arthritis and rheumatism.

[9]  A. Laupacis,et al.  Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. , 2005, Archives of internal medicine.

[10]  S. Suissa,et al.  Cyclooxygenase-2 Selective Nonsteroidal Anti-Inflammatory Drugs and the Risk of Ischemic Stroke: A Nested Case-Control Study , 2006, Stroke.

[11]  Donald Rubin,et al.  Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.

[12]  G. Sarosi,et al.  Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: a historical cohort analysis. , 2004, Gastroenterology.

[13]  Sebastian Schneeweiss,et al.  Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults , 2004, Circulation.

[14]  J. Emberson,et al.  Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials , 2006, BMJ : British Medical Journal.

[15]  Robert Riddell,et al.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.

[16]  Y. Lacasse,et al.  From the authors , 2005, European Respiratory Journal.

[17]  J. Avorn,et al.  Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. , 2006, Arthritis and rheumatism.

[18]  P. Duncan,et al.  Stroke: who's counting what? , 2001, Journal of rehabilitation research and development.

[19]  D. Dewitt,et al.  Cox-2-selective inhibitors: the new super aspirins. , 1999, Molecular pharmacology.

[20]  R. Sperling,et al.  Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). , 2002, The American journal of cardiology.

[21]  E. Fisher,et al.  Studying Outcomes and Hospital Utilization in the Elderly: The Advantages of a Merged Data Base for Medicare and Veterans Affairs Hospitals , 1992, Medical care.

[22]  T. Grosser,et al.  Role of Prostacyclin in the Cardiovascular Response to Thromboxane A2 , 2002, Science.

[23]  G. Singh,et al.  NSAID induced gastrointestinal complications: the ARAMIS perspective--1997. Arthritis, Rheumatism, and Aging Medical Information System. , 1998, The Journal of rheumatology. Supplement.

[24]  E. Fisher,et al.  The accuracy of Medicare's hospital claims data: progress has been made, but problems remain. , 1992, American journal of public health.

[25]  G. Hankey,et al.  Cyclooxygenase-2 Inhibitors: Are They Really Atherothrombotic, and If Not, Why Not? , 2003, Stroke.

[26]  Debashis Singh,et al.  FDA to review risks of antidepressants in adults , 2004, BMJ : British Medical Journal.

[27]  R J Little,et al.  Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. , 2000, Annual review of public health.

[28]  J. Avorn,et al.  Relationship Between COX-2 Specific Inhibitors and Hypertension , 2004, Hypertension.

[29]  W. Ray,et al.  Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. , 1991, Annals of internal medicine.

[30]  S. Shoor,et al.  Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study , 2005, The Lancet.

[31]  Validation of administrative data used for the diagnosis of upper gastrointestinal events following nonsteroidal anti‐inflammatory drug prescription , 2006, Alimentary pharmacology & therapeutics.

[32]  J P Rissing,et al.  Physician and coding errors in patient records. , 1985, JAMA.

[33]  喬 嶋本.  Nested Case-control Study , 1992, Definitions.

[34]  P. Schoenfeld.  Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. , 1999, The American journal of medicine.

[35]  D. Graham,et al.  Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase-2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study , 2005 .

[36]  C Michael Stein,et al.  Cardiovascular toxicity of valdecoxib. , 2004, The New England journal of medicine.

[37]  R. Hunt,et al.  Gastrointestinal safety profile of nabumetone: a meta-analysis. , 1999, The American journal of medicine.

[38]  L. J. Passman,et al.  Elderly Veterans Receiving Care at a Veterans Affairs Medical Center While Enrolled in Medicare-Financed HMOs : Is the Taxpayer Paying Twice? , 1997, Journal of general internal medicine.

[39]  W. Ray,et al.  COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease☆ , 2003 .

[40]  Marc A Pfeffer,et al.  Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2005, The New England journal of medicine.

[41]  N. Caporaso,et al.  Ascertainment of mortality in the U.S. veteran population: World War II veteran twins. , 1995, Military medicine.

[42]  M. Reilly,et al.  The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. , 2004, Journal of the American College of Cardiology.

[43]  D. Graham,et al.  NSAIDs and gastrointestinal complications: new clinical challenges , 2005, Expert opinion on pharmacotherapy.

[44]  Han K. Kang,et al.  Vital status ascertainment through the files of the Department of Veterans Affairs and the Social Security Administration. , 1996, Annals of epidemiology.

[45]  J. Vane,et al.  Cyclooxygenases 1 and 2. , 1998, Annual review of pharmacology and toxicology.

[46]  S A Rich,et al.  The coxibs, selective inhibitors of cyclooxygenase-2. , 2001, The New England journal of medicine.

[47]  R. D'Agostino.  Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .

[48]  S. Normand,et al.  Positive predictive value of the diagnosis of acute myocardial infarction in an administrative database , 1999, Journal of General Internal Medicine.

[49]  P. McGettigan,et al.  Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. , 2006, JAMA.

[50]  M. Reilly,et al.  Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction , 2005, Annals of Internal Medicine.

[51]  R. Sperling,et al.  Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib , 2001, Circulation.

[52]  S. Shakir,et al.  Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data. , 2003, Rheumatology.

[53]  Eric R. Ziegel,et al.  Survival analysis using the SAS system , 1995 .

[54]  P. Duke,et al.  Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. , 2003, The Journal of thoracic and cardiovascular surgery.

[55]  C Michael Stein,et al.  COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease , 2002, The Lancet.

[56]  R. Makuch,et al.  Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. , 2003, The American journal of cardiology.

[57]  S. Hill,et al.  Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis , 1996, BMJ.

[58]  J. Hallas,et al.  Risk of Stroke Associated With Nonsteroidal Anti-Inflammatory Drugs: A Nested Case-Control Study , 2003, Stroke.

[59]  J. Cheng,et al.  Significance of non-level walking on transtibial prosthesis fitting with particular reference to the effects of anterior-posterior alignment. , 2001, Journal of rehabilitation research and development.

[60]  W. White,et al.  Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. , 2002, The American journal of cardiology.

[61]  Charles A. Day,et al.  Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. , 2004, Atherosclerosis.

[62]  R Day,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.